Adjuvant FLOT provides survival benefit for oesophagogastric junction and gastric adenocarcinoma patients with low tumour regression after neoadjuvant chemotherapy

Documenti analoghi

• Adherens junction protein expression is associated with poor response to neoadjuvant FLOT chemotherapy and pro‐inflammatory tumor microenvironment in esophageal adenocarcinoma
  di: Bastian Grothey, et al.
  Pubblicazione: (2026)
• Treatment of local recurrence of esophageal cancer following Ivor‐Lewis esophagectomy—Experiences of a high‐volume center
  di: Karl Knipper, et al.
  Pubblicazione: (2024)
• Targeting the receptor tyrosine kinase MerTK shows therapeutic value in gastric adenocarcinoma
  di: Naita Maren Wirsik, et al.
  Pubblicazione: (2024)
• Synchronous gastric adenocarcinoma and gastrointestinal stromal tumour
  di: Preekesh Suresh Patel, et al.
  Pubblicazione: (2025)
• Utilization and survival outcomes of neoadjuvant chemotherapy for early‐stage gastric cancer
  di: Lauren M. Janczewski, et al.
  Pubblicazione: (2024)